Roche signs new deal with PTC, this time in the area of spinal muscular atrophy
Roche has received exclusive worldwide rights to genetic disorder biotech PTC Therapeutics Inc.’s program for the rare muscle weakening disease spinal muscular atrophy. The deal includes three preclinical small molecules, which could enter human testing within 18 months, plus back-up compounds.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com